Suppr超能文献

相似文献

1
EphA2 overexpression promotes ovarian cancer growth.
Cancer Biol Ther. 2008 Jul;7(7):1098-103. doi: 10.4161/cbt.7.7.6168. Epub 2008 Apr 19.
2
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70. doi: 10.1093/jnci/djj414.
3
EphA2 expression is associated with aggressive features in ovarian carcinoma.
Clin Cancer Res. 2004 Aug 1;10(15):5145-50. doi: 10.1158/1078-0432.CCR-03-0589.
4
Dual targeting of EphA2 and FAK in ovarian carcinoma.
Cancer Biol Ther. 2009 Jun;8(11):1027-34. doi: 10.4161/cbt.8.11.8523. Epub 2009 Jun 24.
5
EphA2 overexpression is associated with angiogenesis in ovarian cancer.
Cancer. 2007 Jan 15;109(2):332-40. doi: 10.1002/cncr.22415.
6
EphA2 induces metastatic growth regulating amoeboid motility and clonogenic potential in prostate carcinoma cells.
Mol Cancer Res. 2011 Feb;9(2):149-60. doi: 10.1158/1541-7786.MCR-10-0298. Epub 2011 Jan 4.
7
Periostin promotes ovarian cancer angiogenesis and metastasis.
Gynecol Oncol. 2010 Nov;119(2):337-44. doi: 10.1016/j.ygyno.2010.07.008. Epub 2010 Aug 4.
8
Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression.
FASEB J. 2005 Nov;19(13):1884-6. doi: 10.1096/fj.05-4038fje. Epub 2005 Sep 15.
9
[EphA2 promotes angiogenesis and metastasis of head and neck squamous cell carcinoma in vivo].
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2012 Jan;47(1):53-7.
10
EphA2 as a target for ovarian cancer therapy.
Expert Opin Ther Targets. 2005 Dec;9(6):1179-87. doi: 10.1517/14728222.9.6.1179.

引用本文的文献

1
Leveraging Multi-omics to Disentangle the Complexity of Ovarian Cancer.
Mol Diagn Ther. 2025 Mar;29(2):145-151. doi: 10.1007/s40291-024-00757-3. Epub 2024 Nov 18.
3
5
in gastrointestinal cancer: Expression, regulation and clinical significance.
World J Gastrointest Oncol. 2022 May 15;14(5):973-988. doi: 10.4251/wjgo.v14.i5.973.
7
The role of EphA7 in different tumors.
Clin Transl Oncol. 2022 Jul;24(7):1274-1289. doi: 10.1007/s12094-022-02783-1. Epub 2022 Feb 2.
8
Noncoding RNA therapeutics - challenges and potential solutions.
Nat Rev Drug Discov. 2021 Aug;20(8):629-651. doi: 10.1038/s41573-021-00219-z. Epub 2021 Jun 18.
9
Serum Exosomal EphA2 is a Prognostic Biomarker in Patients with Pancreatic Cancer.
Cancer Manag Res. 2021 May 7;13:3675-3683. doi: 10.2147/CMAR.S304719. eCollection 2021.
10
Prediction of the treatment response in ovarian cancer: a ctDNA approach.
J Ovarian Res. 2020 Oct 19;13(1):124. doi: 10.1186/s13048-020-00729-1.

本文引用的文献

1
Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism.
J Cell Sci. 2008 Feb 1;121(Pt 3):358-68. doi: 10.1242/jcs.017145. Epub 2008 Jan 15.
2
A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells.
Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3208-18. doi: 10.1158/1535-7163.MCT-07-0200.
6
EphA2 overexpression is associated with angiogenesis in ovarian cancer.
Cancer. 2007 Jan 15;109(2):332-40. doi: 10.1002/cncr.22415.
7
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70. doi: 10.1093/jnci/djj414.
9
EphA2 as a target for ovarian cancer therapy.
Expert Opin Ther Targets. 2005 Dec;9(6):1179-87. doi: 10.1517/14728222.9.6.1179.
10
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.
Cancer Res. 2005 Aug 1;65(15):6910-8. doi: 10.1158/0008-5472.CAN-05-0530.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验